Premature Ovarian Insufficiency
Transcript of Premature Ovarian Insufficiency
Premature Ovarian Insufficiency
Michael Savvas
King’s College Hospital
Premature Ovarian Insufficiency
•Loss of ovarian function before the age of 40
•Affects 1% of women
•Affects 0.1% of women before age of 30
•May present with subfertility
POI causes
• Idiopathic
• Iatrogenic
• Auto immune
• X Chromosome abnormalities
• Familial Genetic Causes
• Viral infection
• Sickle cell disease
• HIV
Diagnosis of Menopause
Women >45 years – Clinical diagnosis
Consider using a FSH test to diagnose menopause only:
•In women aged 40 to 45 years with menopausal symptoms
•in women aged under 40 years in whom menopause is suspected
NICE 2015
Premature Ovarian insufficiency
Diagnosis in women aged under 40 years is based on:
•Menopausal symptoms, including no or infrequent periods
•Elevated FSH levels on 2 blood samples taken 4–6 weeks apart.
AMH unhelpful
POI Investigation
•Auto antibodies
Unhelpful
•Chromosomal analysis
Primary amenorrhoea
Family history
Premature Ovarian Insufficiency
•Symptoms
•Long term
Infertility
Osteoporosis
Heart disease
Dementia
Increased mortality
Symptoms
•Oligo/amenorrhoea
•Hot flushes / night sweats
•Disturbed sleep
•Tiredness
•Cognitive function
•Mood swings
•Dry thin skin
•Hair loss
•Urinary symptoms
•Sexual function
Premature Ovarian Insufficiency
Psychological symptoms
•Depression
•Low levels of self esteem and Life satisfaction
•Sexual Dysfunction
Sexual Function
•Loss of libido
•Anorgasmia
•Vaginal dryness
•Superficial dyspareunia
May be reflection of general well being
Infertility
POF
Most Distressing symptom
Loss of fertility 54%
Feeling Older 27%
Baber, Abdalla and Studd
Premature ovarian Insufficiency
May first present to the fertility specialist
Infertility
Oligo/amenorrhoea
Pregnancy after POI
• Around 5%
• But variable
• No effective intervention to enhance this
Cardiovascular Disease
•Increased risk
CVD Incidence
CVD Mortality
Most marked following surgical menopause
OSTEOPOROSIS
•Increased risk of osteoporosis and fractures
Cognitive Function
•Increased risk of cognitive impairment and dementia
Worse after surgical menopause
Premature Ovarian insufficiency
•Offer HRT or OCP until age of natural menopause
•HRT may have a beneficial effect on blood pressure when compared with a combined oral contraceptive
•HRT is not contraceptive
NICE 2015
HRT
•Alleviates menopausal symptoms
•Reduce risk of long-term sequalae
•Facilitates fertility treatment donor eggs.
HRT
•Oestrogen
•Testosterone
•Progestrone / Progestogen
To protect endometrium
OESTROGEN
PROGESTOGEN
1 14 28
Mimics the normal menstrual cycle
Aims to produce a regular cyclical bleed
Sequential HRT
Altered Sexual Function
•Consider Testosterone if oestrogen alone is not effective
NICE 2015
HRT in POI
•Testosterone
Libido
Moods
Energy
Progestogens
•PMS type symptoms
•?Increased risk of Breast Cancer
•Adverse effects on Lipids
•Regular withdrawal bleed
Micronised progesterone
•Oral /vaginal
•200mg for 12 days
•Lower risk of breast cancer
•Better metabolic profile
•Fewer progestogenic side effects
Routes of Administration
•Oral
•Transdermal patches or gels
•Subcutaneous implants
HRT in POI
•Transdermal route avoids first pass effect through liver
•No increased risk of thrombosis
Cardiovascular Disease
•Initial WHI study suggested increased risk of CVD in all ages
•Subsequent analysis confirms reduction in CVD when HRT started after 60 years
POI and Osteoporosis
HRT is first line
•100 -150 μg transdermal
•2mg oral
•30 μg EE may be less good
•Bisphosphonates best avoided
Bone densitometry every 2-3 years
HRT and cognitive function
•Improved cognition
•Reduced risk of dementia
When commenced early
POI and Breast cancer
•Reduced incidence of breast cancer
•HRT does not increase risk above that in women of same age without POI
•Oestrogen alone associated with reduced risk of breast cancer
POI and Breast cancer
•Combined HRT – Very small increase
Absolute risk is very small
But no increase in mortality
•Progesterone may be safer
Venous Thromboembolism
•Increased risk with oral but not transdermal
•Transdermal in women at increased risk
NICE 2015
HRT
•Benefits outweigh risk if started before the age of 60.
HRT Conclusion
•Can alleviate symptoms
•Long term benefits
Osteoporosis
Heart disease
Overall mortality reduced
Fertility
Age of women giving birth in UK
Fertility Cryopreservation
• Embryo Freezing
• Egg freezing
• Ovarian tissue freezing
• Ideally undertaken when the woman has normal ovarian reserve.
Predicting Premature Ovarian Failure
•Clinical
•Family history
•History of poor ovarian response to stimulation (POR)
•Ovarian reserve testing
Vitrifed donor eggs
Egg Bank Fresh
Age of donor 26 26
Age of recipient 41 41
BMI 22.6 22.5
CPR 50.2% 49.8%
Twins 32.4% 37.5%
Cobo et al Hum Rep 2010
Oocyte Freezing
•Age
•Number of eggs
8-10 eggs in women <35 years
•Increased obstetric complications
•Use of Donor sperm (47%)
Ovarian Tissue Cryopreservation
•Ovarian cortex removed laparoscopically
•Cryopreserved
•Autologous transplantation
•Large number of eggs
Donor egg treatment
Egg donors
• Shortage of altruistic anonymous donors in UK
• Known donors
• Egg Sharing
• Treatment overseas
Egg Donors
• Healthy women, between the
• Age of 18 and 35 years of age
• Should preferably have had healthy children of her own.
• No history of mental disorders.
• There should be no family history of genetic or heritable diseases.
• Infectious screen
Egg Donors
• Donors have no legal rights or obligations to children born as a result of their donated eggs.
• Can be told whether any children were born the sex and the year they were born.
Donor Anonymity
• Since 1 April 2005 are identifiable
• Only donor-conceived person can initiate contact
Egg recipient
• Can be provided with non-identifying information such as height and ethnicity
• Pen portrait
Obstetric outcomes
Donor eggs compared with own eggs
•Increased risk of first trimester bleeding and pregnancy induced hypertension
•Higher caesarean section rate
Stoop et al 2012
Fertility - Conclusion
• Infertility most distressing consequence of POI
• Elective fertility preservation prior to iatrogenic menopause or in young women at risk of POI
• Donor egg treatment remains only treatment option in POI.
Management of POI
• Women with POI require long term support
• HRT until at least age of 51
• Donor egg treatment only effective treatment